Posted from: Tuesday, October 07, 2014 - 04:52 PM - Present

Movantik Approved Opioid-Induced Constipation

September 15, 2014 –The FDA approved Movantik (naloxegol), an oral treatment for opioid-induced constipation unrelated to cancer.  Movantik is manufactured by Nektar Therapeutics and AstraZeneca Plc.

Movantik is in a class of opioid-induced constipation (OIC) drugs are designed to fight the effects of opioid painkillers on the gut without compromising centrally mediated pain relief.

If you have any questions you can contact our Client Services Call Center at 1-877-723-6005.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Sunday, October 20, 2019 - 02:06 PM.